From Doctor Search to Pharmaceutical Company: OpenEvidence Closes Series D, Valuation Rises to $15 Billion
OpenEvidence, an AI search platform for physicians, raised $250 million in Series D funding at a $15 billion post-money valuation. It plans to move its first drug candidate into clinical trials within 2026 while expanding partnerships with Anthropic, MSK, and NCCN.